一、主要会计数据和财务指标 | 持有数量(万股) 名称 | | 占总股本比例 (%) | 增减情况(万 股) | | --- | --- | --- | --- | | 成都天兴仪表(集团)有限公司 | 4400.20 | 13.46 | 不变 | | 宏瓴思齐(珠海)并购股权投资企业(有限合伙) | 3000.00 | 9.18 | 不变 | | 侯颖 | 1492.07 | 4.56 | 不变 | | 高扬 | 534.66 | 1.64 | 不变 | | 王杭义 | 383.33 | 1.17 | 20.00 | | 平潭天祺瑞投资合伙企业(有限合伙) | 200.00 | 0.61 | 不变 | | 成都市贝瑞和康基因技术股份有限公司-第一期员工 持股计划 | 102.92 | 0.31 | 新进 | | 汇添富中证精准医疗指数(LOF)A | 91.18 | 0.28 | 新进 | | 李新胜 | 87.41 | 0.27 | 新进 | | 关炜楠 | 85.00 | 0.26 | 新进 | | 较上个报告期退出前十大股东有 | | | | | MORGAN STANLEY & CO. INTERN ...

成都市贝瑞和康基因技术股份有限公司 2024 年度财务决算报告 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）2024 年度财 务决算编制工作已经完成，上会会计师事务所（特殊普通合伙）对公司 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度合并及母公司利润表、合并及 母公司现金流量表、合并及母公司所有者权益变动表以及财务报表附注进行了审 计，并出具了上会师报字(2025)第 6570 号标准无保留意见的审计报告。现将 2024 年度财务决算情况报告如下： 一、主要会计数据 2024 年，公司实现营业收入 107,816.53 万元，较上年同期减少 6.36%；归 属于上市公司股东的净利润-19,242.85 万元，较上年同期亏损幅度收窄。净利 润下降主要原因为临床业务需求较上年整体有所下滑、行业竞争加剧导致收入下 降，以及公司对联营企业投资损失、计提信用减值损失、资产减值损失等增加所 致。 | 项目 | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入（元） | 1,078,1 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-016 成都市贝瑞和康基因技术股份有限公司 关于聘请2025年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 本次聘请会计师事务所符合财政部、国务院国资委、证监会印发的《国有企 业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开了第十届董事会第十三次会议和第十届监事会第八次会议，审议通过了 《关于聘请 2025 年度审计机构的议案》，同意聘请上会会计师事务所（特殊普通合 伙）（以下简称"上会会计师事务所"）为公司 2025 年度审计机构。本事项尚需提 交公司 2024 年年度股东大会审议通过，现将有关事项公告如下： 一、拟聘请会计师事务所事项的情况说明 为了保持公司审计工作的连续性，便于审计工作的顺利开展和提高审计质量， 公司拟聘请上会会计师事务所为公司 2025 年度审计机构，负责公司 2025 年度的财 务报告和内部控制审计工作，聘期 1 年，并提请 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-015 成都市贝瑞和康基因技术股份有限公司 关于 2025 年度日常关联交易预计的公告 关联交 易类别 关联人 关 联 交 易 内容 关联交 易定价 原则 合同签订金额 或 预 计 金 额 （元） 截 至 披 露 日 已 发 生 金 额 （元） 上 年 发 生 金 额（元） 向关联 人销售 产品、 商品 福建和 瑞及其 子公司 销售设备、 测序试剂 及其他相 关试剂 市场定 价、协 议定价 438,464.60 向关联 人提供 劳务 提供测序 服务/修理 修配、房屋 租赁 市场定 价、协 议定价 500,000.00 127,447.60 409,509.11 接受关 联人提 供的劳 务 采购检测 服务、设备 租赁服务 市场定 价、协 议定价 500,000.00 （二）预计日常关联交易类别和金额 | 向关联 人采购 | | | 采购设备、 测序试剂 | 市场定 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 产品、 | | | 及其他相 | 价、协 | 4, ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-017 成都市贝瑞和康基因技术股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议基本情况 1、会议届次：2024年年度股东大会 2、召集人：公司董事会 召开本次股东大会的议案经公司第十届董事会第十三次会议审议通过。 3、会议召开的合法、合规性：本次股东大会召开符合有关法律、行政法规、部 门规章、规范性文件、深圳证券交易所业务规则和公司章程等的规定。 4、会议时间： 现场会议召开时间：2025年5月20日（星期二）下午14:30 网络投票时间： 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月20 日9:15—9:25、9:30—11:30、13:00—15:00；通过深圳证券交易所互联网投票系统 投票的具体时间为：2025年5月20日9:15—15:00。 5、会议召开方式： 本次股东大会采用现场表决与网络投票相结合的方式。本公司将通过深圳证券交 易所交易系统和互联网投票系统（http://wltp.cninfo ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.08 billion, a decrease of 6.36% compared to ¥1.15 billion in 2023[19]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥192.43 million, an improvement of 54.96% from a loss of ¥427.20 million in 2023[19]. - The net cash flow from operating activities for 2024 was approximately ¥87.97 million, down 20.75% from ¥111.01 million in 2023[19]. - The total assets at the end of 2024 were approximately ¥2.38 billion, a decrease of 13.00% from ¥2.74 billion at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥1.68 billion, down 9.90% from ¥1.86 billion at the end of 2023[19]. - The basic earnings per share for 2024 was -¥0.5443, an improvement of 54.96% from -¥1.2084 in 2023[19]. - The weighted average return on net assets for 2024 was -10.87%, an improvement of 9.64% from -20.51% in 2023[19]. - The company reported a decrease in revenue after deductions, with the adjusted operating revenue for 2024 being approximately ¥1.06 billion compared to ¥1.13 billion in 2023[20]. - The company's total revenue for the first quarter was approximately ¥279.48 million, with a decline to ¥255.50 million in the fourth quarter, representing a decrease of about 8.57%[24]. - The net profit attributable to shareholders was ¥8.24 million in the first quarter, but turned negative in the fourth quarter with a loss of ¥202.81 million[24]. - The net cash flow from operating activities showed significant fluctuations, with a negative cash flow of ¥42.72 million in the first quarter, turning positive to ¥65.07 million in the fourth quarter[24]. Market and Industry Insights - The global gene sequencing market was valued at approximately $15.7 billion in 2021, with expectations to grow to $37.7 billion by 2026, indicating a strong growth trajectory[32]. - The Chinese gene sequencing market is projected to grow from $1.59 billion in 2021 to $4.24 billion by 2026, capturing about 10.13% of the global market[32]. - The government has implemented several policies to promote prenatal diagnosis, which is expected to accelerate the adoption of genetic testing technologies in grassroots medical institutions[31]. Technology and Services - The company focuses on high-throughput sequencing technology and HiFi sequencing technology for genetic testing services, targeting reproductive health and genetic disease detection[33]. - The company aims to leverage advanced sequencing technology combined with artificial intelligence for clinical applications, enhancing service offerings to hospitals and medical laboratories[33]. - The company provides genetic testing services covering over 1,700 single-gene diseases, utilizing innovative third-generation HiFi sequencing technology[34]. - The "Beibian" non-invasive prenatal testing (NIPT) screens for three types of fetal chromosomal aneuploidy (T13, T18, T21) and includes 17 types of chromosomal abnormalities[36]. - The "Beibian Plus" NIPT offers screening for over 100 chromosomal and genomic diseases, as well as large fragment microdeletion syndromes[36]. - The "Beiquan'an" prenatal whole exome sequencing (WES) is widely used for prenatal diagnosis and hereditary disease diagnosis in children and adults[37]. - The company has developed intelligent data interpretation and management services through its smart data center and AI application center[34]. - The company is committed to expanding its research sequencing technology and product services to meet diverse analytical needs and better serve research users[30]. Financial Management and Governance - The company has established an independent financial accounting system, enabling it to independently make financial decisions and maintain a clear separation from the controlling shareholder's finances[117]. - The company maintains a complete and independent business operation, with no competition or unfair related transactions with the controlling shareholder or its affiliates[114]. - The company has a clear separation of its financial operations from the controlling shareholder, with independent banking accounts and tax obligations[117]. - The company has implemented strict approval procedures for any operational funds transactions with related parties, ensuring transparency and compliance[111]. - The company has committed to regular assessments and adjustments of its management systems based on feedback and evaluations[150]. - The company has established a special team to enhance the collection of receivables and assess credit risks associated with customers[176]. Research and Development - The company is currently developing multiple new products based on sequencing platforms, aiming to enhance product performance and expand clinical applications[75]. - The company has ongoing projects for third-generation sequencing technology, with 13 detection products under development[75]. - R&D investment decreased by 12.24% to ¥113,550,557.11 in 2024, accounting for 10.53% of operating revenue[77]. - The number of R&D personnel increased by 9.29% to 200, representing 14.27% of the total workforce[76]. Employee and Management Structure - The total number of employees at the end of the reporting period is 1,402, with 1,397 from major subsidiaries and 5 from the parent company[140]. - The professional composition includes 568 production personnel, 368 sales personnel, 294 technical personnel, 36 financial personnel, and 136 administrative personnel[141]. - The company has established a comprehensive salary system that integrates performance management and salary incentives to align with business development[142]. - The training program includes various branches focusing on professional skills, general workplace skills, cultural promotion, and leadership development[143][144]. Compliance and Risk Management - The company has not reported any significant internal control deficiencies during the reporting period[153]. - The internal control audit report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024[154]. - The company has implemented corrective measures to enhance governance structure and internal controls, resulting in improved operational transparency and compliance[180]. - The company is at risk of technological and product innovation lag, which could affect market share and profit margins[103]. - The company is managing increasing accounts receivable as its business scales, which poses a risk of bad debts[105]. Strategic Partnerships and Collaborations - The company has established strategic partnerships with leading global suppliers like Illumina and PacBio to stay updated on market changes and technology trends[54]. - The company is actively pursuing market expansion through strategic partnerships and investments in biotechnology and real estate sectors[96]. Future Outlook - The company aims to improve operational efficiency and reduce risks associated with land and asset development through strategic asset sales[96]. - The company has outlined plans for future growth, emphasizing the importance of maintaining a strong financial position and operational capabilities[96].

一、召开情况 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-022 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第八次会议于 2025 年 4 月 23 日在北京市昌平区生命园路 4 号院 5 号楼 8 层会 议室以现场会议的方式召开，会议通知已于 2025 年 4 月 11 日以邮件形式发送给 各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事会会 议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生主 持，董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 二、审议情况 成都市贝瑞和康基因技术股份有限公司 第十届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 报告期内公司监事会严格按照《中华人民共和国公司法》《深圳证券交易所 上市公司自律监管指引第 1 号—主板上市公司规范运作》《公司章程》《监事会 议事规则》等有关法律、法规、规范性文件勤勉尽责地开展各项工作，全体监事 认真负责、勤勉尽职完成各项 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-023 成都市贝瑞和康基因技术股份有限公司 第十届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第十三次会议于 2025 年 4 月 23 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2025 年 4 月 16 日以 邮件形式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。 本次董事会会议应出席董事 7 名，实际出席会议董事 7 名，会议由董事长高扬先 生主持，董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法 规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审议通过《2024 年年度报告全文及摘要》 表决结果：7 票同意，0 票反对，0 票弃权。 本议案会前已经公司董事会审计委员会审议通过，并同意提交公司董事会审 议。 年度报告全文及摘要将同日刊登在巨潮资讯网（www.cninfo ...

贝瑞基因（000710）公告，2024年营业收入10.78亿元，同比下降6.36%。归属于上市公司股东的净亏损 1.92亿元，去年同期净亏损4.27亿元。基本每股收益-0.5443元/股。公司计划不派发现金红利，不送红 股，不以公积金转增股本。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-013 成都市贝瑞和康基因技术股份有限公司 2024年度利润分配的预案 一、2024年度利润分配预案 经上会会计师事务所（特殊普通合伙）审计，成都市贝瑞和康基因技术股份 有限公司（以下简称"公司"）2024年度合并报表实现归属于母公司股东的净利 润为-192,428,499.73元，母公司实现净利润为-54,274,897.70元，截至2024年 12月31日，母公司累计未分配利润为-354,297,787.52元，合并报表累计未分配 利润为64,542,377.86元。根据合并报表、母公司报表中可供分配利润孰低的原 则，2024年度实际可供分配的利润为0元。 公司拟定2024年度利润分配预案为：2024年度不派发现金红利，不送红股， 也不进行资本公积金转增股本。 项目 本年度 上年度 上上年度 现金分红总额（元） 0 0 0 回购注销总额（元） 0 44,511,181.27 0 归属于上市公司股东 的净利润（元） -192,428,499.73 ...